[go: up one dir, main page]

FI980822A0 - Pharmaceutical composition on the skin or mucosal surface of the active substance or through the skin or mucosa surface - Google Patents

Pharmaceutical composition on the skin or mucosal surface of the active substance or through the skin or mucosa surface

Info

Publication number
FI980822A0
FI980822A0 FI980822A FI980822A FI980822A0 FI 980822 A0 FI980822 A0 FI 980822A0 FI 980822 A FI980822 A FI 980822A FI 980822 A FI980822 A FI 980822A FI 980822 A0 FI980822 A0 FI 980822A0
Authority
FI
Finland
Prior art keywords
skin
pharmaceutical composition
active substance
mucosa
mucosal
Prior art date
Application number
FI980822A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI980822A (en
Inventor
Lise Sylvest Nielsen
Jens Hansen
Original Assignee
Gs Dev Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gs Dev Ab filed Critical Gs Dev Ab
Publication of FI980822A publication Critical patent/FI980822A/en
Publication of FI980822A0 publication Critical patent/FI980822A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI980822A 1995-10-12 1998-04-09 Pharmaceutical composition on the skin or mucosal surface of the active substance or through the skin or mucosa surface FI980822A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK115095 1995-10-12
PCT/DK1996/000437 WO1997013528A1 (en) 1995-10-12 1996-10-11 A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface

Publications (2)

Publication Number Publication Date
FI980822A FI980822A (en) 1998-04-09
FI980822A0 true FI980822A0 (en) 1998-04-09

Family

ID=8101575

Family Applications (1)

Application Number Title Priority Date Filing Date
FI980822A FI980822A0 (en) 1995-10-12 1998-04-09 Pharmaceutical composition on the skin or mucosal surface of the active substance or through the skin or mucosa surface

Country Status (7)

Country Link
EP (1) EP0871489A1 (en)
JP (1) JPH11513393A (en)
AU (1) AU702030B2 (en)
CA (1) CA2231273A1 (en)
FI (1) FI980822A0 (en)
NO (1) NO981633L (en)
WO (1) WO1997013528A1 (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440980B1 (en) 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
CA2286052A1 (en) * 1997-04-17 1998-10-29 Lise Sylvest Nielsen A novel bioadhesive drug delivery system based on liquid crystals
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
WO1999007341A1 (en) * 1997-08-09 1999-02-18 Smithkline Beecham Plc Compositions for nasal administration
ES2202901T3 (en) * 1997-09-09 2004-04-01 Lyotropic Therapeutics, Inc. COVERED PARTICLES, PROCEDURE FOR MANUFACTURING AND USE.
SE9703458D0 (en) * 1997-09-25 1997-09-25 Pharmacia & Upjohn Ab Nicotine compositions and methods of formulation thereof
WO1999060012A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
US7030155B2 (en) 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9827034D0 (en) * 1998-12-10 1999-02-03 Univ Manchester Delivery formulation
ATE280571T1 (en) * 1999-08-06 2004-11-15 Max Delbrueck Centrum IMPLANTABLE ACTIVE DEPOSIT
WO2001045727A2 (en) * 1999-12-20 2001-06-28 New Pharma Research Sweden Ab Stabilized veterinary compositions comprising more than one antiviral agent
DE10057769A1 (en) 2000-11-22 2002-05-23 Beiersdorf Ag Use of a composition for cosmetic or dermatological hair care products, comprises dispersed liquid crystals forming a cubic phase as a base
HUP0400732A3 (en) * 2001-04-30 2007-05-29 Trommsdorff Arzneimittel Pharmaceutically active uridine esters
US7439271B2 (en) * 2001-06-27 2008-10-21 The Gillette Company Reduction of hair growth
US20030124196A1 (en) 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
JP2007504256A (en) * 2003-09-01 2007-03-01 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド Compositions and methods for delivery of bioactive agents
NZ551990A (en) 2004-06-04 2011-01-28 Camurus Ab Liquid depot formulations
EP1812022B1 (en) 2004-09-28 2014-01-15 Atrium Medical Corporation Stand-alone film and methods for making the same
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
WO2006036982A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Drug delivery coating for use with a stent
DE602005026998D1 (en) 2005-01-14 2011-04-28 Camurus Ab SOMATOSTATIN-ANALOG FORMULATIONS
PL1848403T3 (en) * 2005-01-14 2010-09-30 Camurus Ab Topical bioadhesive formulations
KR100983746B1 (en) * 2005-01-14 2010-09-24 카무러스 에이비 Somatostatin-like formulation
SI1845942T1 (en) * 2005-01-14 2014-06-30 Camurus Ab Gnrh analogue formulations
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
AU2005325510B2 (en) 2005-01-21 2009-07-02 Camurus Ab Pharmaceutical lipid compositions
CA2607626A1 (en) * 2005-05-10 2006-11-16 Novartis Ag Modified release famciclovir pharmaceutical compositions
CA2609810C (en) 2005-06-06 2012-05-22 Camurus Ab Glp-1 analogue formulations
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
AU2006304590A1 (en) 2005-10-15 2007-04-26 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
MX2009004038A (en) 2006-10-17 2009-08-24 Nuvo Res Diclofenac gel.
EP2626091B1 (en) 2006-11-06 2016-09-28 Atrium Medical Corporation Coated surgical mesh
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
US8783089B2 (en) * 2008-06-09 2014-07-22 Boehringer Ingelheim International Gmbh Device and method for determining the properties of aerosol formulations
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
US8618164B2 (en) 2009-03-31 2013-12-31 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
US8546450B1 (en) 2009-03-31 2013-10-01 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
WO2010150262A2 (en) * 2009-06-25 2010-12-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Reverse hexagonal mesophases (hii) and uses thereof
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US10322213B2 (en) 2010-07-16 2019-06-18 Atrium Medical Corporation Compositions and methods for altering the rate of hydrolysis of cured oil-based materials
WO2013174978A1 (en) 2012-05-25 2013-11-28 Camurus Ab Somatostatin receptor agonist formulations
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
NZ704012A (en) 2012-07-26 2017-09-29 Camurus Ab Opioid formulations
EP3326613A1 (en) 2012-07-26 2018-05-30 Camurus AB Opioid formulations
EP3612166A4 (en) 2017-04-20 2020-11-04 Zeenar Enterprises Pty Ltd Liquid crystalline dosage form for administering a statin
JP7603972B2 (en) * 2018-09-07 2024-12-23 株式会社ファルネックス External preparations containing non-lamellar liquid crystal forming lipids
CA3117606A1 (en) * 2018-10-25 2020-04-30 Zeenar Enterprises Pty Ltd Composition that forms liquid crystalline particles
CN111821254B (en) * 2019-04-18 2021-10-15 华东师范大学 A kind of antiviral hydrogel and its preparation method and application
CN111759858B (en) * 2020-06-02 2022-09-20 杭州英健生物科技有限公司 PH-sensitive digestive tract mucosa protective gel and application thereof
CN112791047A (en) * 2021-01-15 2021-05-14 中国人民解放军总医院第三医学中心 A kind of resveratrol layered liquid crystal and preparation method thereof
EP4419884A2 (en) * 2021-10-19 2024-08-28 Sensach AB Lipid patch
WO2023189273A1 (en) * 2022-03-28 2023-10-05 富士フイルム株式会社 Biological composition
WO2023189270A1 (en) * 2022-03-28 2023-10-05 富士フイルム株式会社 Biomaterial composition
WO2024068672A1 (en) * 2022-09-26 2024-04-04 Universität Bern Structured lipid compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2631282A1 (en) * 1976-07-12 1978-01-19 Kali Chemie Pharma Gmbh Increasing solubility of pharmaceutical used e.g. in gelatin capsules - by dissolving in fatty acid mono:glyceride cpds. and then rapidly cooling
SE457933B (en) * 1987-07-06 1989-02-13 Larsson Kare PHARMACEUTICAL COMPOSITION INCLUDING A WATER DISPERSED MIXTURE OF LIPIDS, MONOGLYCERIDES AND PHOSPHATIDYLCOLINE AND ITS APPLICATION FOR THE PREPARATION OF A GASTRONIN TESTINALLY EFFECTIVE COMPOSITION
DK0448091T3 (en) * 1990-03-23 1999-05-03 Yoshitomi Pharmaceutical Pharmaceutical preparation containing a poorly water-soluble drug
CA2186750C (en) * 1994-03-30 2008-08-05 Jens Hansen Use of fatty acid esters as bioadhesive substances

Also Published As

Publication number Publication date
WO1997013528A1 (en) 1997-04-17
AU702030B2 (en) 1999-02-11
NO981633L (en) 1998-06-04
FI980822A (en) 1998-04-09
AU7279296A (en) 1997-04-30
JPH11513393A (en) 1999-11-16
NO981633D0 (en) 1998-04-08
CA2231273A1 (en) 1997-04-17
EP0871489A1 (en) 1998-10-21

Similar Documents

Publication Publication Date Title
FI980822A0 (en) Pharmaceutical composition on the skin or mucosal surface of the active substance or through the skin or mucosa surface
DE69830095D1 (en) Pharmaceutical, cosmetic or dermo-pharmaceutical patch for the administration of several different active substances
BR9610153A (en) Pharmaceutical formulations
BR9611626A (en) Pharmaceutical formulations
ITMI950568A0 (en) PHARMACEUTICAL FORMULATIONS IN THE FORM OF THIXOTROPIC GEL
NO962606L (en) Pharmaceutical composition
ID24654A (en) OMEPRAZOLA PHARMACEUTICAL FORMULATION
BR9607317A (en) Peptides and pharmaceutical composition
BR9607318A (en) Peptides and pharmaceutical composition
IS5665A (en) Pharmaceutical pressure spray composition
EE04390B1 (en) Topical preparation for the treatment of dermatological conditions
FI953515L (en) Pharmaceutical formulations of fluoxetine
PT907364E (en) PHARMACEUTICAL COMPOSITION OF SUSTAINED LIBERTACAO
NO981008D0 (en) Pharmaceutical formulation
IT1295645B1 (en) APPARATUS FOR THE ELECTRO-EMANATION OF ACTIVE INGREDIENTS.
PT754407E (en) LIQUID FORMULATIONS OF 1,2-BENZISOYLAZOLIN-3-ONA
EE200000226A (en) 3,6-Half-Ketals of the 9a-Azalides, Method of Preparation and Pharmaceutical Composition
LV11727A (en) Pharmaceutical composition
FI973229L (en) New pharmaceutical composition
BR9806083A (en) Pharmaceutical composition for the treatment of hapattite c
PT1017388E (en) Pharmaceutical composition containing IBUPROFEN AND DOMPERIDONE FOR THE TREATMENT OF ENXAQUECA
FI973280A0 (en) Pharmaceutical composition
TR199600583A2 (en) Increasing the tolerability of amino acids with pharmaceutical activity.
FI973230A0 (en) New pharmaceutical formulation
BR9606066A (en) Compound and pharmaceutical formulation